Oct. 27 at 2:08 PM
$SNDX revenue multiples v 5 peer comm'l-stage non-oncology focused bios that received FDA approvals in the last 3 years.
Analysts forecast SNDX to generate roughly the same revenue dollars over the next 5 years as 3 of these peers
$MESO $TARS &
$ARQT yet SNDX trades at just about half their valuations. SNDX reported a gross profit margin of 96% last quarter. Are these peers' revenues more valuable?
The 2 others with much higher revenue expectations also trade @ higher multiples.
$SLNO was way off after a patient death last month that analysts say was unrelated to their therapy yet still trades @ a meaningfully higher multiple.
This is not investment advice. We have no idea if SNDX's share price will move higher in the future. All the same, what if analyst estimates are credible & if SNDX is worth a peer revenue multiple (2 BIG ifs).
Be careful the attached data may be inaccurate. Do not rely on the attachment. Mistakes have been noted before.
